Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Recognizing the potential of semaglutide for weight management, researchers developed Wegovy, a higher-dose version of semaglutide approved in 2021 explicitly for chronic weight management in patients with obesity or overweight with at least one weight-related comorbidity
In fact, the medication comes with a warning for women to stop taking the drug two months before becoming pregnant, as risks to the pregnancy and foetus are not known
doi: 10.1210/en.2013-1934 44 PanjwaniNMulvihillEELonguetCYustaBCampbellJEBrownTJet al
This study follows other similar research that showed a reduced risk of alcohol and tobacco consumption, as well as reduced risk of psychosis and other mental health disorders
US$ 23.37
US$ 20.19
US$ 25.64
